New stock news | Micatex Hong Kong IPO prospectus invalid

Shenzhen Maitland Biomedical Technology Co., Ltd. (referred to as Maitland) submitted its Hong Kong stock prospectus on September 11, 2025, which expired after 6 months on March 11, 2026. Morgan Stanley and Huatai International were its joint sponsors at the time of submission. The prospectus shows that Maitland is a global medical solutions provider, offering an innovative and comprehensive product portfolio that meets the clinical needs of a wide range of clinical departments, wards, clinics in medical institutions, as well as community health centers, testing institutions, and home care settings. As of June 30, 2025, Maitland has commercialized over 50 life support products, 80 minimally invasive intervention products, and 210 in vitro diagnostic products. These products come in various models to meet different application needs. By the final practicable date, Maitland's products have been distributed in over 140 countries and regions globally. In China, Maitland's products have been used in over 6,000 hospitals, including approximately 90% of tertiary class A hospitals, covering 31 provinces, municipalities, and autonomous regions.